OTSUKA - EXECUTED -C-26-18-007-3-00 .PDF

NOV 28 2018

ny MARICOPA COUNTS
REQUEST FOR EXECUTION OF DOCUMENTLERK BOARD OF SUPta is

TO: Fran McCarroll, Clerk of the Board
Board of Supervisors
Tenth Floor, Administration Building

DATE: 1 1 127 / 1 8 cH C-26-18-007-3-00, C-26-18-008-3-00, C-26-18-009-3-00

Submitting Department: Correctional Health Services

. Outpatient Sample Program for Long Acting Injectable Antipsychotic Medications
Title of Document: p P a g ak Poy

11/21/18 6/27/18

Date of Legal Review: Date of Board Approval:
Copy of Agenda Item Attached (AIF)
Original Enclosed for Official Filing

Number of copies enclosed

(Include desired number of copies in addition to the original which is retained for the official files.)

Return Copies to: Carolynn Morris
LocationiAddress 204 N. Central Suite 5000
Phoenix, AZ 85004

Date Executed and Returned: lle rs

0 pal”

Agenda Item Id:

Item Title
AGREEMENT FOR OUTPATIENT SAMPLE PROGRAM WITH OTSUKA AMERICA PHARMACEUTICAL, INC

C Number: C-26-18-007-3-00

Action Requested:

Adopt a Resolution which authorizes an Agreement between Otsuka America Pharmaceutical, Inc. and
Maricopa County through the Department of Correctional Health Services, for the purpose ofa free
medication for psychiatric patients. Approve and authorize, by Resolution, Maricopa County by and
through its Department of Correctional Health Services (MCDCHS), to process a non-financial Outpatient
Sample Program (OSP) form (ONRHA052A 32176004) with Otsuka America Pharmaceutical, Inc., for free
samples of ABILIFY MAINTENA (APRIPIPRAZOLE) for extended-release injectable suspension. This
Agreement is non-financial and is effective from June 27, 2018 until June 27, 2023.

Board Required Information:
Long acting injectable (LAI) antipsychotic medications are used frequently in the community for
psychiatric conditions, including schizophrenia, schizoaffective disorder, and bipolar disorder.

Given the large number of jail inmates with psychiatric conditions who get treated with LAI medications
in the community, best practices dictate that these medications be continued in jail for patients who are
stable and compliant on LAls.

The cost of LAls is significant. On average, 200 patients per month are receiving injectable antipsychotic
medications in Maricopa County Jails. This comprises 20% of the monthly pharmacy budget for a jail
population of 7500.

Fortunately, pharmaceutical companies understand the burden that LAls have on county budgets and
have programs designed specifically to provide medications, free of charge, to incarcerated populations.

Creating a partnership with these companies will allow for continuity of care on patients, while in jail,
who are stable and compliant in the community with LAI medications.

It will also allow for ‘new starts’ on patients who are good candidates (either those who have been on
LAls in the past, or who may benefit from doing a trial of LAls for the first time).

Additional Information:
Recent medical literature indicates that adherence to antipsychotic medications may lead to a decrease
in criminal recidivism.

RESOLUTION: C-26-18-007-3-00

OUTPATIENT SAMPLE PROGRAM WITH OTSUKA AMERICA PHARMACEUTICAL, INC.
LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS

WHEREAS, an average of 200 inmate patients per month receive long acting injectable antipsychotic
(“LAI”) medications comprising of 20% of the monthly pharmacy budget for a jail population of 7500;

WHEREAS, recent medical literature indicates that adherence to antipsychotic medication may lead to a
decrease in criminal recidivism, and where patients are carefully selected for LAI treatment, in
combination with discharge planning and “warm handoffs,” there is the potential of decreasing the
recidivism of this vulnerable patient population;

WHEREAS, partnering with pharmaceutical companies to receive LAI medications free-of-charge,
Maricopa County Correctional Health Services will be able to continue these treatments on stable patients
and to initiate therapy on candidates who may benefit the most;

NOW THEREFORE:

BE IT RESOLVED that the Board of Supervisors hereby adopts Resolution: C-26-18-007-3-00 and
authorizes Maricopa County by and through its Department of Correctional Health Services (MCDCHS),
to process a non-financial Outpatient Sample Program (OSP) form (ONRHA052A 32176004) with Otsuka
America Pharmaceutical, Inc., for free samples of ABILIFY MAINTENA® (APRIPIPRAZOLE) for extended-
release injectable suspension.

Dated this ow day of Maven ver

IN WITNESS WHEREOF, the parties agree to enter into this agreement:

, 2018.

APPROVED AS TO FORM: FOR AND ON BEHALF OF
MARICOPA COUNTY

‘N
Attorney for Maricopa County By Ce

hfe lI f Chairman, Board of SUpérvisors
Date NOV 28 2018
Date
ys ATTEST:
Qi CPktirl/ Jeli
VEDI CAL DI RETO CHS ‘Clerk of the Board OF
W248 NOY 28 2018

DATS Date

RESOLUTION: C-26-18-007-3-00

OUTPATIENT SAMPLE PROGRAM WITH OTSUKA AMERICA PHARMACEUTICAL, INC.
LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS |

WHEREAS, an average of 200 inmate patients per month receive long acting injectable antipsychotic
(“LAI”) medications comprising of 20% of the monthly pharmacy budget for a jail population of 7500;

WHEREAS, recent medical literature indicates that adherence to antipsychotic medication may lead to a
decrease in criminal recidivism, and where patients are carefully selected for LAI treatment, in
combination with discharge planning and “warm handoffs,” there is the potential of decreasing the
recidivism of this vulnerable patient population;

WHEREAS, partnering with pharmaceutical companies to receive LAl medications free-of-charge,
Maricopa County Correctional Health Services will be able to continue these treatments on stable patients
and to initiate therapy on candidates who may benefit the most;

NOW THEREFORE:

BE IT RESOLVED that the Board of Supervisors hereby adopts Resolution: C-26-18-007-3-00 and
authorizes Maricopa County by and through its Department of Correctional Health Services (MCDCHS),
to process a non-financial Outpatient Sample Program (OSP) form (ONRHA052A 32176004) with Otsuka
America Pharmaceutical, Inc., for free samples of ABILIFY MAINTENA® (APRIPIPRAZOLE) for extended-
release injectable suspension.

Dated this of day of i lotonler , 2018.

IN WITNESS WHEREOF, the parties agree to enter into this agreement:

APPROVED AS TO FORM: FOR AND ON BEHALF OF
MARICOPA G COUNTY

Atterney for Maricopa County By Co. (te

t/a iI f Chairman, Board of Supervisors
Date Noy 2.8 28
Date
a ATTEST: — \
ez etn) Neal
HEDI CAL DIPECICE- CHS Clerk of the Board 08 FW
ufos Hoy 28 20I8

tATS ; Date